Carboxypolymethylene clinical trials
Also written Carbomer.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses carboxypolymethylene is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Huaxia Eye Hospital Group (1) · LanZhou University (1) · Tung Wah Hospital (1) · Sun Yat-sen University (1)
Studies
Open first, then newest update. How each study uses carboxypolymethylene is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Effects of Two Tear Substitutes in Patients With Dry Eye SyndromeCompletedNot applicableHuaxia Eye Hospital GroupNCT03211351Written as Liposic
- Sjögren's Syndrome Is Associated With Meibomian Gland DysfunctionStatus unknownNot applicableLanZhou UniversityNCT03434106Written as liposic
- Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?Status unknownNot applicableTung Wah HospitalNCT03060005Written as liposic
- Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye SyndromeStatus unknownNot applicableSun Yat-sen UniversityNCT02992392Written as Liposic
Given beside what is tested · 1 — carboxypolymethylene is usual care or a partner of the new treatment
Codes
What other systems call carboxypolymethylene · ClinicalTrials.gg INT002382
- MeSH (NLM) C006912carboxypolymethyleneOne source NLM
- UNII (FDA) 0A5MM307FCCARBOMER HOMOPOLYMER, UNSPECIFIED TYPEConfirmed FDA, NLM
- RxNorm 20298One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C006912 | carboxypolymethylene | One source NLM |
| UNII (FDA) | 0A5MM307FC | CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE | Confirmed FDA, NLM |
| RxNorm | 20298 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.